Brii Biosciences Limited (HK:2137)
:2137
Want to see HK:2137 full AI Analyst Report?
Top Page
Brii Biosciences Limited
(2137)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$1.00
▼(-30.56% Downside)
Action:Reiterated
Date:04/25/26
The score is primarily held back by weak financial performance (persistent losses, revenue contraction, and ongoing cash burn), partially offset by a relatively strong, low-debt balance sheet. Technicals add further caution with the stock below key longer-term moving averages, while valuation remains challenging due to negative earnings and no indicated dividend support.
Positive Factors
Low Leverage / Strong Balance Sheet
A very low debt load and sizable positive equity provide durable financial flexibility for a biotech firm. This reduces refinancing risk, supports funding of clinical and commercial activities through uneven cash flows, and cushions the company during long R&D timelines.
Negative Factors
Persistent Operating Losses
Ongoing, deep operating losses indicate the business has not reached scalable, self-sustaining operations. Persistent negative margins erode equity over time, require continued external funding, and make it harder to achieve durable profitability even if revenues stabilize.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
A very low debt load and sizable positive equity provide durable financial flexibility for a biotech firm. This reduces refinancing risk, supports funding of clinical and commercial activities through uneven cash flows, and cushions the company during long R&D timelines.
Read all positive factors
Brii Biosciences Limited (2137) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$779.55M
Dividend YieldN/A
Average Volume (3M)6.36M
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue GrowthN/A
EPS Growth55.86%
CountryHK
Employees98
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding734,530,500
10 Day Avg. Volume5,897,564
30 Day Avg. Volume6,360,478
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.38
Price to Sales (P/S)50.44
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Brii Biosciences Limited Business Overview & Revenue Model
Company Description
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patient...
How the Company Makes Money
Brii Biosciences primarily makes money through biopharmaceutical commercialization and partnering-based economics tied to its product portfolio. Key revenue streams typically include: (1) product sales revenue from commercialized medicines (where ...
Brii Biosciences Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.12M | 54.29M | 56.32M | 51.63M | 92.54M |
| Gross Profit | 0.00 | 54.29M | 56.32M | 51.63M | 92.54M |
| EBITDA | -290.29M | -392.51M | -168.20M | -503.58M | -602.80M |
| Net Income | -216.86M | -508.16M | -174.83M | -484.31M | -4.12B |
Balance Sheet | |||||
| Total Assets | 2.36B | 2.71B | 3.20B | 3.39B | 3.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.94B | 2.33B | 2.66B | 3.00B | 3.35B |
| Total Debt | 8.93M | 28.02M | 3.16M | 12.66M | 21.62M |
| Total Liabilities | 36.22M | 100.55M | 125.87M | 234.35M | 300.44M |
| Stockholders Equity | 2.38B | 2.66B | 3.12B | 3.19B | 3.34B |
Cash Flow | |||||
| Free Cash Flow | -288.42M | -376.12M | -643.62M | -635.57M | -880.49M |
| Operating Cash Flow | -286.55M | -372.89M | -594.01M | -496.28M | -879.46M |
| Investing Cash Flow | -151.31M | 895.47M | -104.35M | -1.43B | -475.76M |
| Financing Cash Flow | -39.12M | -9.41M | -10.98M | -3.04M | 3.23B |
Brii Biosciences Limited Technical Analysis
Negative
1.44
Price Trends
1.33
Negative
1.42
Negative
1.64
Negative
Market Momentum
-0.07
Positive
27.32
Positive
12.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Negative. The current price of 1.44 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.33, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 27.32 is Positive, neither overbought nor oversold. The STOCH value of 12.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2137.
Brii Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | HK$16.77B | 83.39 | 11.29% | ― | 40.78% | 410.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.73B | 25.32 | 43.89% | ― | 150.60% | ― | |
47 Neutral | HK$779.55M | -3.15 | -14.48% | ― | ― | 55.86% | |
44 Neutral | HK$2.66B | -3.29 | -22.28% | ― | -9.18% | -142.22% | |
43 Neutral | HK$2.34B | -9.48 | 11.40% | ― | -90.96% | 77.66% | |
41 Neutral | HK$667.86M | -2.86 | -28.13% | ― | -33.80% | 31.52% |
* Healthcare Sector Average
HK:2137
Brii Biosciences Limited
1.10
-0.71
-39.23%
HK:2181
Mabpharm Limited
0.40
-0.08
-16.67%
HK:2197
Clover Biopharmaceuticals Ltd.
1.74
1.49
596.00%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
41.82
24.32
138.97%
HK:6628
Transcenta Holding Limited
1.53
0.04
2.68%
HK:6660
AIM Vaccine Co., Ltd. Class H
2.10
-1.76
-45.60%
Brii Biosciences Limited Corporate Events
Brii Biosciences Warns Hepatitis B Drug Program at Risk Amid Vir Arbitration
May 22, 2026
Brii Biosciences has disclosed that its ongoing arbitration with U.S.-based Vir Biotechnology over a collaboration and license agreement has stalled progress on elebsiran, an siRNA therapy candidate targeting hepatitis B. The dispute stems from al...
Brii Biosciences Data Backs Shorter NRTI Use in Next-Generation HBV Therapies
Apr 26, 2026
Brii Biosciences has presented new data at the Asian Pacific Association for the Study of the Liver meeting in Istanbul, detailing a cross-study analysis of post-treatment hepatitis B surface antigen rebound in NRTI-experienced patients from its P...
Brii Biosciences Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority
Apr 23, 2026
Brii Biosciences Limited has called its annual general meeting for June 16, 2026, to be held online via the Vistra eVoting Portal, where shareholders will review and adopt the audited financial statements for the year ended December 31, 2025, and ...
Brii Biosciences Launches Arbitration Against Vir Over Hepatitis B Drug Manufacturing Rights
Apr 16, 2026
Brii Biosciences has initiated arbitration proceedings in the United States against its collaboration partner Vir Biotechnology over alleged breaches of a 2018 Collaboration, Option, and License Agreement and a 2024 letter agreement governing the ...
Brii Biosciences Narrows 2025 Loss as Costs Fall and Revenue Emerges
Mar 19, 2026
Brii Biosciences reported its annual results for the year ended December 31, 2025, showing an emerging revenue base and a significantly narrowed loss. The company’s bank deposits and cash and cash equivalents declined 19.6% to RMB1,941.0 mil...
Brii Biosciences Confirms 2025 PFIC Status, Issues Tax Statement for U.S. Holders
Mar 19, 2026
Brii Biosciences Limited has notified its U.S. shareholders that it met the definition of a Passive Foreign Investment Company for the tax year ended December 31, 2025, and has issued a PFIC Annual Information Statement for that period. The compan...
Brii Biosciences Sets March 2026 Board Meeting to Approve 2025 Annual Results
Mar 9, 2026
Brii Biosciences Limited has scheduled a board meeting for March 19, 2026 to review and approve its audited annual results for the year ended December 31, 2025. The board will also consider publication of these results and address other corporate ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.